Pmv Pharmaceuticals Inc (PMVP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pmv Pharmaceuticals Inc (PMVP) has a cash flow conversion efficiency ratio of -0.204x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.58 Million) by net assets ($71.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PMVP stock market capitalisation for the company's overall valuation and market capitalisation.
Pmv Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Pmv Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pmv Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pmv Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Pmv Pharmaceuticals Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hainan Airlines Co Ltd B
SHG:900945
|
0.547x |
|
Kumpulan Perangsang Selangor
KLSE:5843
|
0.017x |
|
Konka Group Co Ltd
SHE:200016
|
0.069x |
|
Broadway Financial Corporation
NASDAQ:BYFC
|
0.015x |
|
5E Advanced Materials Inc
AU:5EA
|
-0.057x |
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
0.071x |
|
SG&G Corporation
KQ:040610
|
0.002x |
|
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
|
0.175x |
Annual Cash Flow Conversion Efficiency for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Pmv Pharmaceuticals Inc from 2018 to 2025. View Pmv Pharmaceuticals Inc (PMVP) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $104.71 Million | $-73.58 Million | -0.703x | -141.26% |
| 2024-12-31 | $176.08 Million | $-51.28 Million | -0.291x | -18.10% |
| 2023-12-31 | $225.69 Million | $-55.66 Million | -0.247x | +4.84% |
| 2022-12-31 | $246.03 Million | $-63.76 Million | -0.259x | -71.71% |
| 2021-12-31 | $308.56 Million | $-46.57 Million | -0.151x | -65.56% |
| 2020-12-31 | $359.12 Million | $-32.74 Million | -0.091x | -129.12% |
| 2019-12-31 | $-70.47 Million | $-22.07 Million | 0.313x | -4.82% |
| 2018-12-31 | $-46.14 Million | $-15.18 Million | 0.329x | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more